Dbv technologies chief medical officer sells shares worth 1,269
DBVT Stock | USD 3.90 0.83 27.04% |
Slightly above 56% of DBV Technologies' investor base is looking to short. The analysis of the overall investor sentiment regarding DBV Technologies suggests that many traders are alarmed. DBV Technologies' investing sentiment can be driven by a variety of factors including economic data, DBV Technologies' earnings reports, geopolitical events, and overall market trends.
DBV |
Dbv technologies chief medical officer sells shares worth 1,269
Read at investing.com
DBV Technologies Investor Sentiment by Other News Outlets
Investor sentiment, mood or attitude towards DBV Technologies can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
DBV Technologies Fundamental Analysis
We analyze DBV Technologies' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of DBV Technologies using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of DBV Technologies based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Cash Per Share
Cash Per Share Comparative Analysis
DBV Technologies is currently under evaluation in cash per share category among its peers. Cash per Share is a ratio of current cash on hands or in the banks of the company to a total number of shares outstanding. It is used to determine a firm's liquidity and is a good indicator of the overall financial health of a company. Value investors often compare this ratio to the current stock quote, and if it exceeds the stock price they would invest in it.
DBV Technologies Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with DBV Technologies stock to make a market-neutral strategy. Peer analysis of DBV Technologies could also be used in its relative valuation, which is a method of valuing DBV Technologies by comparing valuation metrics with similar companies.
Peers
DBV Technologies Related Equities
OPT | Opthea | 10.81 | ||||
LYRA | Lyra Therapeutics | 10.53 | ||||
TARS | Tarsus Pharmaceuticals | 3.17 | ||||
MNOV | MediciNova | 2.99 | ||||
IPHA | Innate Pharma | 2.67 | ||||
EWTX | Edgewise Therapeutics | 2.48 | ||||
IKNA | Ikena Oncology | 2.37 | ||||
CNTA | Centessa Pharmaceuticals | 1.76 | ||||
RZLT | Rezolute | 1.00 | ||||
ANEB | Anebulo Pharmaceuticals | 0.70 | ||||
ITOS | Iteos Therapeutics | 0.12 | ||||
NUVL | Nuvalent | 0.08 | ||||
MOLN | Molecular Partners | 0.17 | ||||
CELC | Celcuity LLC | 0.39 | ||||
ORIC | Oric Pharmaceuticals | 0.70 | ||||
EPIX | ESSA Pharma | 1.10 | ||||
ELYM | Eliem Therapeutics | 1.30 | ||||
GNFT | Genfit | 1.41 | ||||
INBX | Inhibrx | 2.37 | ||||
HCWB | HCW Biologics | 6.00 |
Additional Tools for DBV Stock Analysis
When running DBV Technologies' price analysis, check to measure DBV Technologies' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy DBV Technologies is operating at the current time. Most of DBV Technologies' value examination focuses on studying past and present price action to predict the probability of DBV Technologies' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move DBV Technologies' price. Additionally, you may evaluate how the addition of DBV Technologies to your portfolios can decrease your overall portfolio volatility.